Invention Grant
- Patent Title: CD38 protein antibody and application thereof
-
Application No.: US16968994Application Date: 2019-02-11
-
Publication No.: US11713357B2Publication Date: 2023-08-01
- Inventor: Ming Lv , Xiaoran Ding , Shiwei Miao , Bin Tan , Xuegong Wang
- Applicant: HANGZHOU SUMGEN BIOTECH CO., LTD. , SUMGEN MAB (BEIJING) BIOTECH CO., LTD.
- Applicant Address: CN Zhejiang
- Assignee: HANGZHOU SUMGEN BIOTECH CO., LTD.,SUMGEN MAB (BEIJING) BIOTECH CO., LTD.
- Current Assignee: HANGZHOU SUMGEN BIOTECH CO., LTD.,SUMGEN MAB (BEIJING) BIOTECH CO., LTD.
- Current Assignee Address: CN Zhejiang; CN Beijing
- Agency: Honigman LLP
- Agent Thomas A. Wootton, Esq.; Jonathan P. O'Brien
- Priority: CN 1810144817.4 2018.02.12
- International Application: PCT/CN2019/074806 2019.02.11
- International Announcement: WO2019/154421A 2019.08.15
- Date entered country: 2020-08-11
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/28 ; A61P35/00 ; A61P35/02 ; C12N5/10 ; A61K48/00 ; A61K31/713 ; C12N15/63 ; A61K39/00

Abstract:
Provided by the invention is an antibody or an antigen-binding fragment thereof, which binds to a CD38 protein at a KD value below 1×10-9M. The antibody or an antigen-binding fragment thereof has strong specific recognition and binding capabilities for CD38 protein, and may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and/or apoptosis. Further provided by the present invention is an application of the antibody or antigen-binding fragment thereof in preventing and treating tumors.
Public/Granted literature
- US20210024645A1 CD38 PROTEIN ANTIBODY AND APPLICATION THEREOF Public/Granted day:2021-01-28
Information query